Sarepta Therapeutics, Inc. (SRPT) stock analysis
Healthcare · Biotechnology
From the 10-K filed 2026-03-02
How it makes money
Sreapta earns revenue by selling approved genetic and RNA-targeted therapies for rare neuromuscular disorders like Duchenne muscular dystrophy.
It commercializes four FDA-approved products for Duchenne: EXONDYS 51, VYONDYS 53, AMONDYS 45, and ELEVIDYS. Revenue depends heavily on physician prescription rates, patient identification, and securing adequate reimbursement from government payors, managed care organizations, and private insurers.
Earnings are driven by the ability to maintain market access and reimbursement duration, while navigating complex prior-authorization and re-authorization processes required for patients who initially obtained coverage.
What protects it: the moat
It protects its earnings through proprietary technology platforms, patented genetic structures, and strategic collaborative partnerships.
Management claims its proprietary PMO chemistry platform and unique AAVrh.74 vector provide technological advantages that are difficult for competitors to replicate. It also relies on patent protection and trade secrets to preserve its proprietary rights.
However, these protections depend on ongoing patent maintenance and the successful defense against competitors developing alternative therapies for the same disease areas.
What growth costs
It continually reinvests in research and development, clinical trials, and manufacturing capabilities to expand its genetic therapeutic pipeline.
Reinvestment focuses on advancing next-generation precision medicines, siRNA programs through partnerships like Arrowhead, and gene therapy product candidates. It also invests in operationalizing its manufacturing strategy and scaling production capabilities for clinical and commercial demands.
The filing does not disclose specific dollar figures allocated to these separate growth and maintenance efforts.
What could damage it
An adverse outcome in confirmatory clinical trials could lead to withdrawal of accelerated approvals, permanently impairing product earnings.
If confirmatory trials fail to verify clinical benefit, regulatory authorities may withdraw approval for products currently operating under accelerated pathways, stripping the company of its primary revenue streams.
About Sarepta Therapeutics, Inc.
Sarepta Therapeutics, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery and development of RNA-targeted therapeutics, siRNA platform, gene therapy, and other genetic therapeutic modalities for the treatment of rare diseases. It offers EXONDYS 51 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 51 skipping; VYONDYS 53 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 53 skipping; AMONDYS 45 for the treatment of Duchenne in patients who have a confirmed mutation of the dystrophin gene that is amenable to exon 45 skipping; and ELEVIDYS, an AAV-based gene therapy, which is contraindicated in patients with any deletion in exon 8 and/or exon 9 in the Duchenne gene. The company also develops SRP-9003, a gene therapy program for the treatment of LGMD2E; SRP-1001 to selectively target and knockdown DUX4 using RNAi in Phase 1/2a clinical trials; and SRP-1003 for reduction of expression of the DMPK gene in Phase 1/2a clinical trials. It has collaboration and license agreements with F. Hoffman-La Roche Ltd; Arrowhead Pharmaceuticals, Inc.; University of Western Australia; Nationwide Children's Hospital; Hansa Biopharma; and Duke University. The company was incorporated in 1980 and is headquartered in Cambridge, Massachusetts.